Sandoz Reports Results of Omnitrope (biosimilar- somatropin) in PATRO Children Study for the Treatment of Turner Syndrome
- The PATRO Children- post marketing surveillance study evaluates biosimilar rhGH (Omnitrope) vs reference rhGH (Genotropin) in 348 children with TS at 130 centers across EU. In this study- 81.6% were rhGH naïve- and 90.2% were prepubertal
- The results demonstrated that the therapy was safe & effective in real-life clinical practice- was generally well tolerated with no unexpected safety signals.
- Mean duration of treatment was 38.5mos.- 48.9% experienced AEs substantial height gains in prepubertal individuals aged 3+ yrs. Additionally- 49.4% of patients discontinued the study
| Ref: Centre for Biosimilar| Image: Reuters
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].